Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E-based Antibody-Drug Conjugate for Treatment of Nectin-4-expressing Cancers

Overexpression of nectin cell adhesion protein 4 correlates with cancer progression and poor prognosis in many human malignancies. Enfortumab vedotin (EV) is the first nectin-4-targeting antibody-drug conjugate (ADC) approved by the FDA for the treatment of urothelial cancer. However, inadequate eff...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Molecular cancer therapeutics 2023-08, Vol.22 (8), p.913-925
Hauptverfasser:	Zhou, Wei, Fang, Peng, Yu, Dongan, Ren, Hongyuan, You, Meng, Yin, Long, Mei, Fei, Zhu, Huikai, Wang, Zhenzhen, Xu, Hui, Cao, Yuxia, Sun, Xiaowei, Xu, Xiaohong, Bi, Jianjun, Wang, Jin, Ma, Lanping, Wang, Xin, Chen, Lin, Zhang, Yongliang, Cen, Xiaowei, Zhu, Xi, Lou, Liguang, Liu, Datao, Tan, Xiaoding, Yang, Jinliang, Meng, Tao, Shen, Jingkang
Format:	Artikel
Sprache:	eng
Schlagworte:	First Disclosures
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!